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Key Points:


Large-scale, randomized trials to evaluate efficacy of positive airway pressure (PAP) for
improving patient-reported outcomes and clinical endpoints associated with obstructive
sleep apnea (OSA) including cardiovascular and metabolic disease have been largely
negative.



Several design-related criticisms have plagued the large-scale PAP trials with a common
focus on PAP non-adherence among trial participants.



Advancing large-scale PAP trial methods to optimize PAP adherence is crucial if the field
is to be successful in generating valid knowledge of the causal effect of OSA on
comorbid outcomes.



“Best trial practices” that focus on optimizing PAP adherence in large-scale trials are
needed.

Synopsis:
Large-scale randomized trials of positive airway pressure (PAP) efficacy have been largely
negative yet PAP adherence was notably sub-optimal across the trials. To address this
limitation, evidence-based PAP adherence protocols embedded within the larger trial protocol
are recommended. The complexity of such protocols will be dependent on adequacy of
resources, including funding and inclusion of behavioral scientist experts on the scientific team,
and trial-specific considerations (e.g., target population) and methods. Recommendations for
optimizing PAP adherence in large-scale trials are set forth that address rigor and
reproducibility.
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Where to Next for Optimizing Adherence in Large-scale Trials of PAP?
Introduction
Clinical trials are defined as experiments in humans designed to evaluate the effects of
specific treatment(s), or exposure condition(s), by reducing random error and bias. 5 Effects or
outcomes evaluated in clinical trials commonly include safety, dosing, efficacy and
effectiveness. Phase III trials that evaluate efficacy and/or effectiveness of a treatment
compared to a standard, alternative or placebo are often designed as large-scale to ensure
adequate statistical power and potentiate generalizability to the defined target population.5 For
the purpose of this paper, large-scale trial characteristics include the following: 1) multi-site; 2)
total sample size greater than 300 participants; and 3) a primary outcome evaluation period
greater than or equal to three months.
In the field of sleep medicine, large-scale trials that meet the above criteria and
examined the effects of positive airway pressure (PAP) are relatively recent to the literature.
Driven in part by prior large epidemiological or observational studies of obstructive sleep apnea
(OSA) and associated comorbidities,6-10 these large-scale trials1-3,11-13 examined the effects of
PAP on comorbid outcomes, OSA outcomes and/or preventative effects for associated
comorbidities such as cardiovascular, metabolic and neurological outcomes. Whereas such
trials would expectedly provide the field with confirmatory evidence and advance the cycle of
research for translation to practice, there have instead been questions raised about the validity
of the results due to design and methodological concerns. PAP adherence has consistently
been an area of concern for many of these trials, expressed clearly in noteworthy editorials that
have accompanied, or followed, the publication of the large-scale trials of PAP.14-19 This review
will use the recent large-scale trial experience to (1) identify opportunities for increasing rigor,
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reproducibility and transparency of forthcoming and future large-scale, prospective trials of PAP
effects and (2) set forth “best trial practices” that directly address PAP adherence while also
considering key methodologies and opportunities relative to implementing health behavior
strategies embedded within a larger trial design.
Large-scale Clinical Trials of PAP
In a systematic database search of PubMed Plus, Scopus and ClinicalTrials.gov that
employed a keyword search strategy (OSA, continuous positive airway pressure [CPAP],
randomized controlled trial [RCT] or trial) with delimiters for adult and publication date from 2000
to current [February 1, 2020], six trials were identified that additionally met criteria for: (1) the
large-scale definition employed herein, (2) an objective measurement of PAP use/adherence,
and (3) reported PAP use in the primary results publication (Table 1). The majority of excluded
trials did not meet the review-specific large-scale definition for sample size or outcome interval
duration or failed to fully report PAP use with the primary results. Across the included trials,
PAP use ranged from 2.3 – 5.0 hours/night (mean or median). In trials reporting a PAP
adherence criterion, approximately half of the samples met the commonly reported PAP
adherence criterion of ≥ 4 hours/night. The trial samples were characteristically similar with the
exception of two trials that had target populations without excessive daytime sleepiness 12 (i.e.,
by Epworth Sleepiness Score criterion) and/or minimally-symptomatic individuals with OSA2
(i.e., absence of other patient-reported OSA symptoms). Studied samples were predominantly
male, middle-aged, obese adults with moderate to severe OSA. All trials set forth a primary
objective to evaluate PAP effects, absent explicit use of the term, “efficacy.” PAP was compared
to at least one other exposure condition, to evaluate the primary outcome assessed at or after
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three months of exposure. Primary outcome results were largely negative, or supportive of the
null hypothesis, across the trials.
Evaluation of efficacy, or the true biological effect of a treatment,5 necessitates exposure
to the test and comparator condition(s) to permit the exploration of patient-reported outcomes
and/or clinical endpoints that are the efficacy outcome(s). Efficacy is evaluated in the trial
setting wherein internal validity is prioritized, notably to the detriment of external validity, or the
generalizability to practice.20 Evaluation of effectiveness, or outcomes of the test and
comparator relative to usual, real-world conditions, may similarly examine biomedical end-points
but, by design, prioritize external validity for addressing practice and policy priorities.20
Effectiveness is the “effect of a treatment when widely used in practice.”5
The identified large-scale trials of PAP all report a primary objective to evaluate the
effect of PAP on a primary endpoint and report designs and analytical methods (e.g., intentionto-treat) consistent with efficacy evaluation. Yet, when the published protocols and primary
results with supporting documents (i.e., supplement, appendix) are carefully scrutinized, the
methodologies and procedures specific to the PAP exposure condition are likened to protocol
methods consistent with effectiveness evaluation. Such methods are reflective of standard
practice, or usual care. For example, a trial that reports providing participants with contact
information for device troubleshooting after providing standard OSA and PAP patient education,
including device set-up and mask fitting for longer large-scale trials, subsumes participants will
acknowledge and recognize specific barriers to PAP use and then initiate contact. This
example is more consistent with standard practice and is thereby better aligned with
effectiveness evaluation wherein the “effect of treatment in practice” is the trial objective. While
effectiveness trials are imperative to the field, efficacy evaluations cannot, and should not be
8
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forgone, as knowledge of PAP efficacy is central to defining treatment standards of OSA by
varied outcomes, including comorbid outcomes of physiological and clinical importance.
Furthermore, efficacy evaluations from randomized trials are viewed as among the strongest
evidence towards answering questions of causality (i.e., does OSA cause comorbid outcomes
of clinical importance).
Rigor and Reproducibility of PAP Adherence Protocols in Large-scale Trials of PAP
Critical insights from the large-scale PAP trials published to date provide the field with an
opportunity to consider how efficacy trials will need to explicitly address PAP adherence within
the larger trial protocol to better meet the requirements for rigor and reproducibility as defined by
National Institutes of Health (NIH)21 and similarly emphasized by other federal agencies.22,23
Trials included herein were designed by teams of interdisciplinary scientific investigators with
relevant expertise (Table 2) and supported by at least one federal or regional agency.
Resources for trial conduct and oversight (internal and external) were clearly explicated in half
of the trial reports,1,3,13 suggesting careful attention to trial operations that is consistent with the
safe, ethical and rigorous conduct of efficacy trials.
There are noteworthy gaps, specific to PAP exposure and PAP adherence protocols,
across the included trials that can be leveraged for optimizing PAP adherence in the next
generation of large-scale trials of PAP efficacy. For example, an absence of evidence-based
behavioral approaches to support PAP use was observed. Some of these gaps are likely
attributed to the state of PAP adherence science at the time of planning and conducting the
trials. Other gaps may be relative to a myriad of contributors including the absence of clear
guidance and/or expectancies for reporting efficacy trial PAP adherence protocols at the time of
grant submission and subsequent publication(s) related to the trial.
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Methods specific to PAP adherence were abstracted from all available published
sources for each trial, including primary results publications, design and methodology
publications, publicly-accessible protocols, trial registry data, grant databases (e.g., RePORTER
for NIH-funded studies), and secondary results publications if available (Table 3; see online
supplement for detailed methods). Corresponding authors identified on the primary results
publication were also contacted when published or publicly-available sources lacked information
or data specific to PAP adherence methods reported in Table 3. Sorting the reported PAP
adherence methods by study period revealed important similarities and differences between
these trials for PAP adherence protocols (Box 1; Box 2).
PAP Adherence Criterion
All trials but one13 identified a PAP adherence criterion, most often defined in the
analysis or results section of the respective published papers. This criterion was consistently
reported as ≥ 4 hours/night of average PAP use without explicit rationale. There were no
methodological details provided for the specified protocol periods during which the criterion was
to have been met; and, if the criterion was not met in any specific interval, there were no reports
of specific PAP adherence protocols that were employed other than “study contact was
initiated.” All trials reported designated visits at which time PAP adherence was electronically
retrieved or downloaded. Two trials1,3 reported using a PAP adherence criterion to guide study
contact with participants; these interactions were either by phone and/or at an additional
research visit to address low PAP adherence. No protocol-based, pre-specified actions were
reported for the low PAP adherence interactions.
Trial PAP Exposure ≤ 4 Months & Adherence Protocols
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All trials reported that mask-fitting, equipment review and education were provided by
trained or experienced study personnel. Only one trial reported the educational approach
employed with participants, using three education modalities to deliver the information.13 No
trials reported specific educational content that was provided to the trial participants. Mask
and/or humidification choice was prioritized relative to adherence in one trial2 while others
specified that humidification and “best-fit” mask were provided.3,13 In some trials,1-3,11 troubleshooting, “support for adapting to PAP” and “advice” were reported as protocol activities in the
first several weeks to four months.
Trial PAP Exposure > 4 Months & Adherence Protocols
All included trials except one13 assessed a primary endpoint with PAP exposure greater
than four months. The SAVE trial3 was the only trial that reported using a specific PAP
adherence protocol extending beyond four months. This trial, with a large number of sites
extending around the globe, was also unique in that a centralized study structure, Sleep
Laboratory Core, was charged with monitoring PAP use across sites and provided centralized
expert advice to sites when PAP adherence was below the study-defined criterion. The SAVE
trial also employed PAP use, leak and residual apnea-hypopnea index (AHI) criteria from PAP
initiation to study end with PAP remote monitoring.3
When the trials are considered collectively, PAP adherence protocols are generally
under-reported, which limits reproducibility and impacts evaluation of the rigor for the reported
work. This weakness limits the potential for other investigators to address the challenge of
optimizing PAP adherence in subsequent large-scale PAP trials. The included trials report
methods that are seemingly consistent with earlier published clinical practice guidelines24 and
with what the field considered “standard practice” at the time of these trials. The PAP
11
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adherence achieved in the included trials is therefore not unexpected given 1) the modest trial
PAP adherence protocols and 2) the observation that across PAP clinical trials and clinical trial
follow-up observational studies, the weighted average of PAP use was 4.46 hours/night and
average non-adherence rate was 36.3%.25 These observed metrics of PAP adherence are
consistent with other reviews that have addressed summary PAP adherence across studies.26,27
The obvious concern is that this level of PAP adherence is sub-optimal for a rigorous
assessment of efficacy.
The overwhelmingly negative results across the large-scale trials coupled with the
minimalist approaches to PAP adherence within the conduct of the efficacy trials provide the
evidence and the necessary motivation for future large-scale trials to carefully design and report
PAP adherence protocols in great detail. These protocols will need to use the current PAP
adherence evidence to potentiate higher PAP adherence across study participants. Such
adherence protocols should be embedded within the larger trial protocol to ensure
reproducibility and strengthen rigor relative to PAP adherence. This approach will best position
large-scale efficacy trials to test PAP by providing results that are unbiased relative to
adherence.
State of the Science: PAP Adherence
Since the earliest large-scale trial1 was conducted, PAP adherence intervention studies
have been increasingly represented in the literature. The body of evidence has recently been
systematically examined, resulting in a meta-analysis4 that supports the current American
Academy of Sleep Medicine’s clinical practice guideline for the PAP treatment of adults with
OSA.28 The meta-analyses addressed PICO (Population, Intervention, Comparison, Outcome)
questions of which eight of the 11 questions included PAP adherence as an outcome (Box 3).
12
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0
Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/bync-nd/3.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042,
USA.

Optimizing Adherence in Trials
Author Deposited Pre-Print
Accepted 5.28.20 by Sleep Medicine Clinics (Special Issue: Unraveling the Puzzle of Adherence in Sleep [Ed.] J. Bakker)

The cumulative set of reviewed evidence (n=1,512) was reduced to a final set of 184 studies
that addressed one or more of the PICO questions;4 for each PICO question, a sub-set of
studies were eligible for meta-analysis. With a pre-specified clinical threshold of significance for
the PAP adherence outcome set at 0.5 hours/night or 10% patient use > 4 hours/night, the
results of the meta-analysis support the accompanying practice guidelines.28 Explicit PAP
adherence interventions addressed by the meta-analyses and subsequent practice guidelines
include educational, behavioral and tele-monitoring recommendations; on average, these
interventions, individually, result in an estimated PAP use effect of 1.0 hour/night (Figure 1).
The available cumulative evidence provides guidance for designing evidence-based PAP
adherence protocols for future large-scale efficacy trials.
Advancing PAP Adherence Protocols in Large-scale PAP Trials
Recommendations for using evidence-based PAP adherence protocols in large-scale
trials include 1) tele-monitoring, 2) behavioral approaches and 3) education. In addition, other
methodologies can be leveraged to improve PAP adherence, including 1) using a PAP run-in
period and 2) considering sampling criteria specific to PAP adherence. Due to the wellrecognized heterogeneity in PAP adherence behavior and factors that are associated with this
behavior,26,27 a multi-component PAP adherence protocol is best-suited for large-scale trials.
Investigative teams will need to carefully balance the complexity and required expertise for
these protocols with feasibility and resource considerations. This is particularly poignant as the
large-scale PAP trials to date have been summarily under-funded (Box 4).
Tele-monitoring
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With the advancement of PAP technology by industry, the field is well-positioned to
objectively measure PAP adherence and capitalize on near real-time treatment usage and
effectiveness data. Future large-scale trials will leverage this technology in PAP adherence
protocols to guide PAP interventions. Study-defined criteria for PAP adherence by study
intervals (e.g., first week, first month) and by near real-time intervals (e.g., within consecutive
days) can be established. This approach, if adjoined with a response-to-PAP use plan (e.g.,
tele-coaching), supports early intervention for PAP non-adherence29 and conservation of
resources within the trial. This is important as evidence from observational studies has
consistently identified that early PAP use is a predictor of long-term PAP use;30,31 similarly,
analyses of PAP trial data has demonstrated the same.32,33 The recommendation for employing
a tele-monitoring and response-to-PAP use protocol within large-scale trials also potentiates
engagement which is a relevant consideration for improving or changing health behavior(s).34-37
Employing both participant- and trial-facing applications and/or web-based portals that may be
industry-supported, or study-specific, are strategies that support PAP use during the active
engagement period;37-42 importantly, PAP use may attenuate after engagement concludes.38
When using industry-supported applications and tele-monitoring platforms, industry partners
bring knowledge on how these digital solutions work and experience from other trials to support
streamlined data acquisition and integration.
When designing the PAP adherence tele-monitoring protocol, the following factors
should be carefully considered: 1) pre-defined usage thresholds in industry-supported telemonitoring solutions and the alignment of these thresholds with trial-defined usage criterion; 2)
centralized and/or site level tele-monitoring and response-to-PAP use responsibilities and
protocols; 3) resources necessary to maintain tele-monitoring protocols; 4) participant burden,
14
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including ethical considerations for informed consent language addressing the schedule of
interactions (i.e., intensity); and 5) innovative approaches that can be employed to automate
tele-monitoring response actions by the trial team, whether at a centralized or site-level, with
specific intention to deliver response actions by communication methods that are defined by
participant preference (e.g., video visits, text messaging, online chat access as opposed to
telephone calls and face-to-face visits).
Behavioral Approaches
Several behavioral approaches for PAP adherence can be considered for large-scale
trials. The field of behavioral sleep medicine has significantly grown over the past 10 years as
has the inter-disciplinary field of experts in behavioral sciences who can provide required
expertise for planning and delivering behavioral approaches for PAP adherence in large-scale
trials. Determining which behavioral approach(s) to embed in a large-scale PAP trial will be
guided by the evidence at the time of planning the trial, expertise of the trial team, schedule of
research visits and/or interactions, and the target population/sample of the trial.
Behavioral interventions tested with positive effects for PAP adherence to date have
been delivered at the outset of PAP treatment (e.g., at PAP initiation) to PAP-naïve adults with
OSA.43-47 Included in this review, one large-scale trial indicated by corresponding author
communication that motivational or cognitive strategies were employed to encourage PAP
adherence without further details; this protocol activity was not reported in the study
publications.11,48 Based on the publications and corresponding author communications, it is
unknown if other trials included in this review also used behavioral approaches for PAP
adherence. It is recommended that these behavioral protocol activities be fully-reported by
future large-scale trials. Reporting guidance that can be used include the SPIRIT guidelines49
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(Standard Protocol Items: Recommendations for Interventional Trials) and TIDier guidelines50
(Template Intervention Description and Replication checklist and guide; both available at
https://www.equator-network.org/. Other important considerations for embedding behavioral
approaches include: 1) timing and format of delivery; 2) centralized and/or site-level oversight,
training and management of behavioral approaches; 3) resources required to maintain delivery
of behavioral approaches during trial execution, including fidelity assessments; 4) participant
burden, including informed consent language addressing the schedule of interactions (i.e.,
intensity); and 5) including a behavioral scientist as a team member with expertise specific to
the phenomenon of PAP adherence, or health behavior.
Education
Disease and treatment education is a practice norm at diagnosis and treatment initiation
in OSA, consistently set forth by consensus24 or strong recommendation.28 Though the effect of
education on PAP adherence is notably modest,4 it is an essential component of behavior
change.51 Education about OSA and PAP was a consistent protocol activity in the trial setting
based on our review of large-scale PAP trials. Considering the diverse (e.g., geographic,
literacy, culture) nature of participants in PAP randomized trials, and to minimize the risk of
excluding sub-groups with different or special needs (e.g., language, visual impairment, low
health and general literacy), the content and delivery mode(s) of education materials should be
designed with attention to these needs. Recent evidence suggests commonly used sleep
education materials that are widely available from American Thoracic Society and American
Academy of Sleep Medicine have high health literacy demands, requiring high school level or
higher education.52 Understandability and clear communication indices of the materials were
also scored low.52 The Centers for Disease Control and Prevention and Agency for Healthcare
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Research and Quality provide explicit guides and information for designing and delivering health
information to varied audiences;53,54 trial teams are urged to use such resources when designing
educational materials (see also: http://centerforhealthguidance.org/health-literacy-principleschecklist.pdf ). If selecting publicly- or commercially-available materials for trial use, evaluation
of the materials with more than readability procedures is important (e.g., Flesch-Kincaid tests).
Other recommendations include 1) consulting with or having a team member with education
expertise specific to the delivery of health information; 2) pilot testing trial education materials
with a representative group of patients and revising materials as indicated; and 3) exploring
multi-modal delivery of educational materials to trial participants at varied study intervals so as
to “off-load” demands at the outset of PAP initiation.
Incentives
The behavioral economics framework assumes that people make decisions with error
and “nudges” are needed to increase the likelihood of good decisions, or decisions that are in a
person’s best self-interest.55,56 Nudges can take many forms including, but not limited to,
incentives and rewards which may be financial in structure. Using incentives and rewards as an
intervention approach for health behavior is an emerging area of study across the literature; yet,
a relatively small body of evidence exists for PAP adherence in patients and no studies, to our
knowledge, report on incentives directed to research sites/teams for PAP behavioral
intervention delivery. Use of incentives in large-scale PAP trials for participants and/or sites and
staff must be considered with caution as the effects, ethics and methodologies are not wellunderstood. As has been recently acknowledged,57 financial incentives do not always work.
There are a myriad of details that must be understood before embedding such incentives in a
study; “the devil is in the detail, because the magnitude of effects differs substantially based on
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the nature of the behavior, the size of the incentive, the population involved, the social context
and the design [of the incentive].”58
If, however, incentives and rewards are conceptualized as non-financial, the ethical
concern for coercive effects and distributive inequity are lessened.58 Such incentives and
rewards, for example, might include de-identified “performance” metrics with comparative
ratings and messages (e.g., “Kudos Reports”), goal tracking worksheets/visualizations to
explicate incremental progress with digital badges and personal rewards-to-self that are based
on self-appraisal metrics. These are but a few examples derived from both behavioral
economics theory and the existing PAP adherence evidence that address goal-directed
behavior change, engagement and motivation. Though the state-of-the-science for financial
incentives for PAP adherence is yet under-developed, incentives are likely to be a consideration
for future large-scale trials with scientific advancement in behavioral economics for sleep and
PAP adherence.59
Run-In Methods
Randomized trials may employ a run-in, or a pre-randomization exposure period to the
active or placebo condition(s), in order to exclude non-adherers, placebo responders, active
condition non-responders or active condition intolerance.60 Run-in methods are not uncommon
in industry and/or pharmacologic trials, but are less common in PAP trials,46 including largescale trials.3 Employing run-in periods is not without controversy however, as external validity is
compromised when a run-in period is used.61 This is because the representativeness of the trial
sample will necessarily differ from the clinical target population. Yet, when efficacy is the
primary aim of the trial, internal validity is prioritized unlike in effectiveness trials. Another
concern to be carefully considered in implementing a run-in period is the impact that a positive
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PAP experience, and positive treatment effects, may have on cross-over rates, wherein subjects
having done well with PAP and then randomized to the comparator condition may decide to
obtain PAP therapy outside the trial. Similarly, in trials where active PAP is compared to
placebo, or sham PAP, and sham PAP or a modified PAP profile (e.g., mask/headgear only) is
used during the run-in, subsequent use of PAP, or adherence, may be affected by the run-in
experience. For example, cognitive perceptions of PAP are different (e.g., lower outcome
expectancies) with sham versus active PAP.62 In addition, when a placebo is the trial
comparator such as with sham PAP, the risk of un-blinding must be carefully navigated when
using run-in methods.
There are important considerations when planning a run-in period for a large scale PAP
trial which include: 1) monitoring run-in data to support fully reporting the number of run-in
exposures conducted, failed run-in rate, and run-in participants’ (failed and completed)
characteristics compared to the trial sample; 2) determining and reporting run-in PAP adherence
criteria which should be consistent with the post-randomization PAP adherence criteria if the
run-in is designed to reduce the overall risk of bias introduced by non-adherence; and 3)
determining if failed run-in will be repeated based on pre-specified criteria. Most trials that have
reported run-in periods have not adequately described the run-in protocol nor run-in results to
address concerns about sample representativeness.63 As of the writing of this review, there are
no published guidelines for run-in period reporting; until such are available, large-scale trials that
employ a run-in period will need to carefully consider the implications of the run-in methods on
the overall trial results. Statistical expertise and trial methodologists are recommended to best
guide these considerations.
Sampling Criteria Methods
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A robust evidence set exists that addresses influential factors on PAP adherence.26,27,64
The evidence suggests that these factors may be measurable at baseline in the efficacy trial
setting and employed as sampling criteria to potentiate PAP adherence. When considering this
approach it is important to reflect on how the selected factors may impact on enrollment rates
and trial sample characteristics. The measurement, or screening, for such factors must also be
feasible using validated instruments. Consideration must be given to the burden of
measurement, ethical decision-making for sampling criteria and timing of measuring such
factors. If predictive factors of PAP adherence are employed as sampling criteria to potentiate
PAP use in the efficacy trial setting, this will necessarily have implications on generalizability.
For this reason, investigators might examine site-level target population characteristics and
determine the effect of imposing the sampling criteria specific to PAP adherence on sample
accrual and characteristics at the trial design phase. This approach may best reduce sampling
feasibility concerns while also providing data-based insights for statements of generalizability.
Future large-scale trial teams will need to remain abreast of emerging evidence for
PAP adherence interventions and employ innovative and tested approaches to best optimize
PAP adherence in the setting of an efficacy trial. No single approach to PAP adherence
interventions within any trial is recommended but rather, embedding evidence-based
interventions that are aligned with:


trial team expertise (see next section, Trial Team Composition),



the a priori threshold for PAP adherence for the end-point,



the estimated PAP use in the target population based on prior published observational
studies or pilot trials, and



trial resources.
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Both investigators and funding agencies will necessarily embrace increasingly complex trial
designs that necessitate thoughtful trial planning periods and nuanced trial management
plans/processes and structures for successfully conducting these trials.
What Does the Future of Large-scale Trials of PAP Look Like?
Designing and conducting the next generation of large-scale PAP trials is a critical
consideration for the field based on recent trial experiences. Explicit opportunities that are
germane to addressing the rigor and reproducibility aspects of large-scale prospective PAP
trials and thereby reducing concerns for internal validity specific to PAP adherence include (1)
trial team composition, (2) operational structure, (3) protocol-within-protocol design, (4) protocol
execution, and (5) trial reporting. By setting forth these recommendations for large-scale PAP
trials, the stage is set for substantive dialogue among investigators, funding agencies and trial
partners (e.g., industry, technology/innovation) in order that “best trial practices” for large-scale
PAP adherence efficacy trials are commonplace.
Trial Team Composition
Adherence to a new health behavior, such as in the trial setting with assignment to PAP
among treatment-naïve adults with OSA, is challenging for both participants and the trial team.
Trial investigators and site staff may have substantial clinical and/or practical experience with
introducing PAP and managing PAP adherence but this is not necessarily transferrable to a trial
setting. For example, unlike research participants who should have equipoise about receiving
PAP therapy, patients presenting for clinical care, by virtue of seeking care, are motivated to
initiate treatment. Also unlike the clinical setting, time-to-adherence is of high importance in
large-scale PAP trials due to pre-defined outcome assessments and study resource-constraints.
21
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0
Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/bync-nd/3.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042,
USA.

Optimizing Adherence in Trials
Author Deposited Pre-Print
Accepted 5.28.20 by Sleep Medicine Clinics (Special Issue: Unraveling the Puzzle of Adherence in Sleep [Ed.] J. Bakker)

Active adherence interventions that consist of more than device/equipment trouble-shooting and
advice may not be well-developed skills among staff and investigators with primarily practicebased experience who manage a wide range of sleep disorders and treatments.
Behavioral science is a distinct field. While investigators of these large-scale trials may
have practical health behavior experience, this does not necessarily equate to depth and
breadth of knowledge and application of behavioral health interventions that are scientificallyderived; nor does such practical experience equate to measurable performance outcomes as is
necessary in these trials. Trial team composition must therefore be carefully considered at the
earliest planning stages of the trial. At the investigator level, a behavioral scientist with
expertise in PAP adherence will ideally be included and lead the protocol for PAP adherence.
This approach will potentiate a scientifically-sound protocol specific to PAP adherence and an
investigator with committed time and focus for this methodological and implementation work.
Another key consideration for team composition is successfully recruiting and retaining
site-level staff members that may, or may not, have relevant experience but who are amenable
to learning and consistently applying behavioral protocol activities as prescribed. Retention of
staff ensures consistency of contact between the trial site and participants. This is similarly
applicable if a centralized structure, or core, is designated for PAP adherence in the trial. Staff
with strong communication skills, including skills for developing rapport and active listening, are
imperative to the success of delivering health behavior interventions such as those with positive
effects for PAP adherence (see Figure 1). These team composition recommendations are
directly supportive of behavioral and implementation science approaches that address
partnership, engagement and collaboration as the cornerstone of health behavior change, 34,65,66
including recent work in the PAP adherence field addressing technology-driven patient
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engagement,37 a vision for patient-centered approaches to OSA and PAP management67 and
emphasis on team approaches for PAP adherence.68
The introduction of stakeholder advisory boards that may include patients, community
leaders and/or clinical providers has emerged as a research priority in many countries, including
the U.S., U.K., Canada and Europe.69 Designing PAP adherence protocols for employ within an
efficacy trial with patient stakeholders has yet to be reported to our knowledge; in fact, patient
engagement across published randomized controlled trials has been limited to date. 69 However
this approach may be an innovative opportunity for large-scale PAP trials. Patient preferences
for protocol activities, for example communication frequency and mechanism, can be accounted
for from the outset of the trial with input from patient stakeholders, or advisors. This may
potentiate participant acceptability of the PAP adherence methods and protocols 70 and thereby,
trial enrollment and retention. Resources for researchers considering engagement approaches
at any study phase, but as suggested here at the trial design level, can be found at Patient
Centered Outcomes Research Institute website
(https://www.pcori.org/engagement/engagement-resources/Engagement-Tool-ResourceRepository).
Operational Structure
From the outset of trial planning, the investigative team should consider the development
of a PAP Adherence Core, a centralized operating structure specific to PAP adherence.
Consistent with the more commonly reported trial structure of a Sleep Reading Core or Sleep
Laboratory Core, the PAP Adherence Core investigators who have scientific and
implementation expertise in health behavior change and PAP adherence will design protocols
specific to PAP adherence that are embedded within the larger trial protocol. Oversight for
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adherence protocols is a central responsibility of the Core, including training, protocol fidelity
and quality of protocol implementation. By centralizing these functions among a dedicated
Core, the necessary knowledge and skill to support site-based staff and investigators for PAP
adherence can be efficiently managed. Increasingly focused intervention approaches to PAP
adherence that are evidence-based can be designed with an expert core; these approaches can
be carefully aligned with the larger trial protocol (i.e., protocol-within-protocol, or a nested
protocol). In order for this approach to be successful, the PAP Adherence Core investigators
must be engaged with the trial investigators/team from the earliest point possible in the design
of the trial and function as active trial team members. This approach will ensure that all trial
activities that bear influence on participants’ use of the test condition will be addressed from a
behavioral perspective from design through results reporting.
Trial Execution
A dedicated PAP Adherence Core will necessarily design and deliver training specific to
PAP adherence protocols. As most large-scale trials include a Training or Education
Committee, the Core will work collaboratively with the larger Committee to ensure all trialspecific standards and expectations are met with delivery of PAP adherence training. In the
setting of large-scale trials that have numerous geographically disperse sites, training
approaches will need to be increasingly innovative yet effective in the delivery to conserve trial
resources (Box 5). Areas of training consideration by the Core will include: training content,
delivery modes and styles of training content, performance standards relative to training
sessions and ongoing monitoring performance standards, certification and re-certification of
staff for all procedures. Contingency training plans for newly hired staff and for those previously

24
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0
Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/bync-nd/3.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042,
USA.

Optimizing Adherence in Trials
Author Deposited Pre-Print
Accepted 5.28.20 by Sleep Medicine Clinics (Special Issue: Unraveling the Puzzle of Adherence in Sleep [Ed.] J. Bakker)

certified staff who demonstrate a need for booster training identified during the protocol fidelity
monitoring procedure is also recommended.
Fidelity monitoring procedures should be designed by the PAP Adherence Core and
monitoring intervals and procedures established in collaboration with relevant trial entities, most
likely to include the Data Coordinating Center (DCC). By establishing partnerships between the
Core and the DCC which is a cornerstone of efficient data monitoring in large-scale trials, fidelity
monitoring of PAP adherence intervention protocols and performance metrics for quality
protocol delivery will be meticulously tracked and communicated to the Core and study
investigators. Thresholds for fidelity and protocol delivery, established by the Core and trial
investigators, will subsequently guide remediation, or booster, training decisions, adjustment of
monitoring intervals, and trial site evaluation and feedback. Though these thresholds are
directly aligned with sub-optimal performance, the Core will also ideally recognize and reward
consistent performance above the threshold and exceptional performance.
Trial Reporting
Reporting of PAP adherence protocols in large-scale trials should be included with the
methodology publication and/or with the primary results publication. Though page limitations
may be prohibitive of a complete reporting of PAP adherence protocols, supplemental or
appendix materials can be used to fully report the protocol. To support both rigor and
reproducibility guidelines, a minimum description of PAP adherence protocols should include:


All intervention approaches employed by protocol period/interval



Complete description of all intervention methods



PAP adherence criterion and rationale

25
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0
Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/bync-nd/3.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042,
USA.

Optimizing Adherence in Trials
Author Deposited Pre-Print
Accepted 5.28.20 by Sleep Medicine Clinics (Special Issue: Unraveling the Puzzle of Adherence in Sleep [Ed.] J. Bakker)



Measurement methods of PAP adherence employed and measurement intervals



Description of training for delivery of intervention(s)



Fidelity monitoring plan including performance thresholds at study- and site-level
When reporting trial results, PAP adherence should be reported as a summary

continuous research variable (mean hours/night) at trial end-point and by study interval for trialrelevant periods (e.g., scheduled recurrent research visits). Because PAP adherence is usually
not normally distributed, reporting PAP use by only mean and standard deviation can be
misleading. Therefore, PAP adherence criterion for the trial should also be reported as a
frequency at trial end-point and by study interval at trial-relevant periods. Any pre-specified perprotocol analyses based on PAP adherence should also be reported with trial results. Protocolbased results that are of importance to report include summary fidelity results at the study-level
and training completion rates, including booster/remediation training conducted throughout the
trial period.
Conclusion
Prospective efficacy trials are requisite to setting forth treatment standards and
guidelines and generate causal effects knowledge. Though innovative comparative
methodologies that employ big data and precision health scientific methods are likely to also
contribute treatment standards and guidelines, prospective efficacy trials of a large-scale nature
will continue to be necessary. Recent efficacy trials of PAP therapy have been challenged by
concerns for validity relative to low PAP use, or non-adherence. Careful scrutiny of these
precedents shed light on opportunities to address PAP adherence in forth-coming and
subsequent trials. In order that PAP adherence is optimized, evidence-based protocols focused
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on PAP use should be embedded within the larger trial protocol. In doing so, investigators will
need to carefully balance numerous factors relative to feasibility, ethical trial conduct and overall
study rigor. Important considerations are highlighted in this review to facilitate dialogue in the
field for “best trial practices” that are specific to PAP adherence, including reporting guidance at
the time of funding application, methodology and results/protocol publications. It is with
attention to these opportunities that there will be reduced concern for the validity of large-scale
PAP trial results and these trials will meet expectancies for rigor and reproducibility.
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Figure 1. Evidence-based PAP Adherence Interventions and their Estimated Improvement for
PAP Adherence.
Caption. Adapted with permission from Patil, et al., 2019. Estimated effects for PAP adherence
(i.e., use) are meta-analyses results reported in Patil, et al., 2019.4
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Table 1. Description of Published Large-scale Trials (n=6)
Trial
(Project
Years)

Location (Sites)

Primary
Endpoint

Follow
-up

Study Sample

Intervention (N)

Comparator
(N)

PAP Use
Criterion

Adherence
h/night

APPLES1
2003 - 2008

US (5)

Neurocognitive
function

6-mo

OSA patients

CPAP
(n=556)

Sham-PAP
(n=542)

≥4

4.2

Spanish
Cohort2
2004 - 2009

Spain (14)

Incident HTN &
CV events

3-yr

OSA patients
(Non-sleepy)

CPAP
(n=358)

No treatment
(n=367)

≥4

5.0

MOSAIC3
2006 - 2010

UK/Canada (10)

CV risk score

6-mo

OSA patients
(Non-sleepy)

CPAP
(n=195)

Usual care
(n=196)

≥4

2.4

HeartBEAT4
2010 – 2012

US (4)

24-hr BP

3-mo

Cardiology patients
with OSA

CPAP (n=106)
Oxygen (n=106)

Lifestyle
education
(n=106)

NR

SAVE5
2008 - 2015

Australia, China,
New Zealand,
India, Spain, US,
Brazil (89)

MACE

4-yr

CVD patients with
OSA

CPAP (n=1359)

Usual care
(n=1358)

≥4

3.3

ISAACC6
2011-2018

Spain (15)

MACE

≥1-yr

ACS patients with
OSA

CPAP (n=633)

Usual care
(n=631)

≥4

2.8

3.5

% ≥4 h

Primary
Outcome
(+ or -)

56.2%

−

64.4%

−

NR

−

NR

+

42%

−

37.5%

−

Notes. APPLES, Apnea Positive Pressure Long-term Efficacy Study; Spanish Cohort Trial; MOSAIC, Multicenter Obstructive Sleep
Apnea Interventional Cardiovascular trial; HeartBEAT, Heart Biomarker Evaluation in Apnea Treatment; SAVE, Sleep Apnea
Cardiovascular Endpoints study; ISAACC, Impact of Sleep Apnea syndrome in the evolution of Acute Coronary syndrome.
Abbreviations- Yr, years; mo, months; h, hours; CPAP, Continuous Positive Airway Pressure; OSA, Obstructive Sleep Apnea; NR,
Not Reported; HTN, Hypertension; CV, cardiovascular; MACE, Major Adverse Cardiovascular Event; CVD, Cardiovascular Disease;
ACS, Acute Coronary Syndrome.
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Table 2. Scientific Trial Team Members by Discipline or Specialty†

Discipline Involved
Sleep Medicine
Respiratory Medicine
Clinical Trialist and/or Statistics
Study-Specific Discipline Relative to Biomedical Focus
Behavioral Science

APPLES
+
+
+
+
-

Spanish
Cohort
+
+
-

MOSAIC HeartBEAT
+
+
+
+

+
+
+
+
-

SAVE

ISAACC

+
+
+
+
-

+
+
+
+
-

Notes. APPLES, Apnea Positive Pressure Long-term Efficacy Study; Spanish Cohort Trial; MOSAIC, Multicenter Obstructive Sleep Apnea
Interventional Cardiovascular trial; HeartBEAT, Heart Biomarker Evaluation in Apnea Treatment; SAVE, Sleep Apnea Cardiovascular Endpoints
study; ISAACC, Impact of Sleep Apnea syndrome in the evolution of Acute Coronary syndrome.
†Identified

by author affiliation(s) in methodology and/or result publication.
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Table 3. Concentration of Methods Specific to Positive Airway Pressure Adherence by Large-scale Trial Study Period (n=6)
Trial Name

Screening
Criteria†
Or
Other PreRandomize
Methods

Random
Assignment‡

APPLES

+

+

+

++

+

++

Spanish Cohort Trial

−

−

++

−

−

−

MOSAIC

+

−

++

−

+

+

HeartBEAT

+

−

+++

−

−

−

+++

+

+++

++

+++

++

+

−

+++

++

++

+

SAVE
ISAACC

PAP
Initiation

Wk 1

Mo 1

> Mo 1

PAP Exposure

Notes. APPLES, Apnea Positive Pressure Long-term Efficacy Study; Spanish Cohort Trial; MOSAIC, Multicenter Obstructive
Sleep Apnea Interventional Cardiovascular trial; HeartBEAT, Heart Biomarker Evaluation in Apnea Treatment; SAVE, Sleep
Apnea Cardiovascular Endpoints study; ISAACC, Impact of Sleep Apnea syndrome in the evolution of Acute Coronary
syndrome.
†Inclusion and Exclusion Criteria that are specified for PAP adherence in methodology and/or result publication and/or
supplemental/appendix materials and/or publicly-availably protocol materials.
‡Reported protocol activities specific to PAP use/initiation/adherence conducted concurrently with randomization.
(−), zero reported method; (+), 1 reported method; (++), 2 reported methods; (+++), 3+ reported methods. See Online
Supplement for detailed reported methods.
Abbreviations – PAP, Positive Airway Pressure; Wk, Week(s); Mo, Month(s).
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Box 1: Consistent PAP Adherence Methods in Large-scale PAP
Efficacy Trials (n=6)




Exclusion Criteria
 Prior PAP use
PAP Initiation
 By trained (or experienced) study personnel
PAP Use Measurement
 Objective at varied study intervals
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Box 2: Exceptional† PAP Adherence Methods in Large-scale PAP Efficacy Trials







Exclusion Criteria
 Other household member w/PAP use1-3
Other Criteria at Screening or Enrollment
 1-wk Run-in with ≥ 3 hours/night average use3
Random Assignment
 20-minute Acclimatize-to-PAP session1
PAP Initiation
 Education about OSA and PAP provided by verbal, audio-visual and written
methods13
 Behavioral sleep medicine specialist provided pre-treatment information about
PAP11*
 Mask and humidification choice2
Exposure Intervals
 PAP use criterion during auto-PAP titration period3
 PAP FAQs for study staff to reduce risk of un-blinding participants (sham vs
CPAP)1
 Core Sleep Lab remote review of PAP use, leak data at regular defined
intervals3
 Core Sleep Lab provide corrective advice to sites, study team as needed3
 Sleep hygiene advice specified by investigators as relevant to PAP adherence
(alcohol and tobacco use, short sleep duration)11
 Week 1 phone f/u1,3
 Week 2 phone f/u11
 Phone f/u based on PAP usage criterion1,3
 Motivational and cognitive strategies used to increase PAP use11*

Notes. †Exceptional defined as reported in ≤50% of included trials. *Not reported in
published methodology or results; provided by corresponding author in response to
electronic mail query requesting any additional protocol activities specific to PAP
adherence.
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Box 3. Summary of PICO Questions and Evidence Density and Quality for Metaanalyses of PAP Adherence Outcome in Patil, et al. 20194
Q4: In-lab vs. Ambulatory PAP titration based on 10 RCTs of high quality
Q5: Auto-titrating vs. continuous PAP based on 23 RCTs of moderate to high quality
Q6: Bi-level PAP or auto-Bi-level PAP vs. CPAP based on 4 RCTs of low quality
Q7: Modified pressure profile vs. no modified pressure profile based on 6 RCTs of low
quality
Q8: Oral vs. nasal PAP mask based on 2 Cross-over RCTs and 1 RCT of low quality
Q9: PAP with humidity vs. no humidity based on 9 RCTs of low to moderate quality
Q10: Educational intervention based on 7 RCTs of moderate quality or
Behavioral intervention based on 6 RCTs of moderate-high quality
vs. No intervention (interventions delivered prior to or during PAP)
 Troubleshooting + education intervention based on 9 RCTs of moderate quality
was separately meta-analyzed
Q11: Tele-monitor guided intervention vs. no tele-monitoring based on 5 RCTs of high
quality
Notes. Abbreviations: PAP, Positive Airway Pressure; vs., versus; RCTs, Randomized
Controlled Trials; CPAP, Continuous Positive Airway Pressure.
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Box 4: Publicly-reported Funding of Large-scale PAP Efficacy Trials (n=6)
Trial Name

Funding Sources†

APPLES

NIH/NHLBI

Spanish Cohort Trial

Sociedad Española de Neumología y
Cirugía Torácica

Not Available

MOSAIC

British Heart Foundation
Oxford Radcliffe Hospitals NHS Trust (UK)

Not Available

HeartBEAT

NIH/NHLBI

$3,679,973

SAVE

National Health and Medical Research
Council (NHMRC)
Philips Respironics (Industry)
Respironics Foundation

$8,904,248

ISAACC

ResMed (Industry)
Fondo de Investigacion Sanitaria (Fondo
Europeo de Desarrollo Regional)

Not available

Publicly
Available Total
Costs‡
$14,094,332

†Funding

source identified in methodology and/or result publication and/or in trial
registry;
retrieved from funding agency database, when publicly-available.
‡Data
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Box 5. Training Approaches for Site Staff in Large-scale PAP Trials: Leveraging
Innovation in Delivery, Format and Style






Baseline Protocol Training
 Face-to-Face Delivery
 Didactic for general protocol information
 Written materials to reinforce didactically delivered content
 Diagrammatic materials for protocol scheme, decision-making
 Teach-teach back for protocol delivery to participants
 Role-play for protocol delivery to participants with peer-to-peer
evaluation
 Case-based learning with participant scenarios
 Review of Manual of Operations (MOP) for PAP adherence protocol
Protocol Training Refreshers
 Pocket Card Deck for PAP adherence protocols and procedures
 Web-based portal with baseline training materials and access to refresher
training materials
 PAP adherence protocol and procedure checklists
Periodic Booster Training (PBT) and New Staff Training After Baseline Training
(NST)
 Web-based synchronous videoconferences: Challenging Scenarios, Casebased Learning approach (PBT)
 Web-based asynchronous Case-based learning (PBT)
 Web-based or Nudge-based Push Notifications to web-based link: Brief
training modules (≤ 5 minutes) (PBT)
 Web-based synchronous and asynchronous training sessions (NST)
 Peer-to-Peer training within sites with expert staff (NST)
 Simulation training by remote access portal/tele-education (NST)
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Supplemental Materials

Where to Next for Optimizing Adherence in Large-scale Trials of PAP?
Amy M. Sawyer, PhD, RN, Douglas M. Wallace, MD, Luis F. Buenaver, PhD,
Alexa J. Watach, PhD, RN, Amy Blase, CCRA, Bruno Saconi, MS, RN,
Sanjay R. Patel, MD, MS, Samuel T. Kuna, MD, Naresh M. Punjabi, MD, PhD

43
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0
Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/bync-nd/3.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042,
USA.

Optimizing Adherence in Trials
Author Deposited Pre-Print
Accepted 5.28.20 by Sleep Medicine Clinics (Special Issue: Unraveling the Puzzle of Adherence in Sleep [Ed.] J. Bakker)

Supplement Table 1. Large-scale Trials Description of Methods Specific to Positive Airway Pressure Adherence by Study
Period
Trial Name
Screening
Random
PAP* Initiation
Wk 1
Mo 1
> Mo 1
(chronologic
Criteria†
Assignment‡
order by
Or Other PreExposure
publication
Randomize
date)
Methods
Exclusion:
20-min PAP
CPAP dispense
1-Wk: phone by Regular contact Regular contact
APPLES1
Prior PAP
habituation
by study
RS X2
w/<4hr/nt use
w/<4hr/nt use
use;
exercise
personnel after
 Ensure use
Other house
before
titration PSG
4-Mo: FTFV w/study
 Manage
member
titration PSG
physician
problems
w/PAP use

PAP use discuss
 Protocol guide
(current or
for PAP FAQs
past)
(reduce risk of
un-blinding)**

Spanish
Cohort
Trial71

NR

NR

MOSAIC2

Exclusion:
Prior PAP use

NR

CPAP dispense
at home after
PSG or unattend
HST at sleep
center
 5hr sleep
 Leak criteria
PAP dispense
by study staff
after randomize
 AutoPAP
 Trained staff

Contact
w/<4hr/nt use
NR

NR

NR

NR

3-Wk FTFV
 PAP f/u

2-Mo Phone
 Advice
 Supplies
4-Mo Phone
 Advice
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 Humidity
optional
 Mask choice

HeartBEAT1
3

Exclusion:
Prior PAP use

NR

APAP dispense
by site
coordinator
w/random assign
 Auto-titrate
X7days
 Then set
pressure

 Supplies
PAP use data download
minimum 1X b/w
initiation-END
 Residual AHI
 Air Leaks
NR

NR

NR

Instruction by
coordinator for
use of assigned
treatment
 Humidity
 Mask-fit by
expert tech
Healthy lifestyle
& sleep
education to
both grps by
slide
presentation,
hard-copy of
slides, publicly
available
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SAVE3

Exclusion:
Neuro deficit
prevent PAP
mask apply;
Prior PAP
use;
Other house
member on
PAP
Other:
1-wk Sham
Run-In to
exclude
unlikely/
unwilling to
adhere to
PAP; patients
informed of
run-in
purpose;
sham device
used; phone
call Run-In
Day 2-3; runin criterion

Written
information
about PAP
View DVD:
Trial
importance &
adherence to
PAP

education
materials (AHA):
 Regular sleep
schedule
 Avoid ETOH
@bed
 Sleep duration
7-8hr/nt
APAP dispense
by study staff
@FTFV
 Best mask fit
 Humidity
 Auto-titrate X7
days
 Set pressure
 Auto-titrate
criteria: ≥3hr/nt
average use,
average leak
<60L/min
 If auto-titration
criterion not
met:
 Address
issues &
repeat
titration X7
days

1-Wk: Phone
RS contact
 Manage
problems
Additional phone
contact if
problems

1-Mo: Remote
review of PAP
data by Core
Sleep Lab
 PAP use
<3hr/nt
 Air leak >60
L/min
 AHI>15/hr

3-Mo & 6-Mo:
Remote review of PAP
data by Core Sleep Lab
 PAP use <3hr/nt
 Air leak >60
L/min
 AHI>15/hr
Q6-Mo: Phone

1-Mo: FTFV as
needed for PAP
problems
Core Sleep Lab
monitors PAP
use, provide
corrective
advice to sites,
study team
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ISAACC11

≥3hr/nt
average
Exclusion:
Prior PAP use

NR

In-hospital
15-Day: Phone
1-Mo: FTFV
3-Mo: FTFV
(enrolled
 Resolve
 Adapt to PAP  Adapt to PAP support
inpatients) APAP
problems
support
 Support PAP adhere
by trained nurse  Phone #
 Support PAP
followed by fixed
provided to
adhere using
pressure PAP
access study
cognitive and
staff any time
motivational
Behavioral sleep
for PAP
strategies**
medicine
problems
 Sleep hygiene
specialist
 FTFV schedule
advice by
provided preprn
sleep unit staff
treatment
at all
information;
scheduled
motivational and
visits; Health
cognitive
behavior
strategies to
advice include
increase PAP
avoid evening
use employed**
ETOH, reduce
tobacco, avoid
short sleep
Notes. APPLES, Apnea Positive Pressure Long-term Efficacy Study; Spanish Cohort Trial; MOSAIC, Multicenter Obstructive Sleep
Apnea Interventional Cardiovascular trial; HeartBEAT, Heart Biomarker Evaluation in Apnea Treatment; SAVE, Sleep Apnea
Cardiovascular Endpoints study; ISAACC, Impact of Sleep Apnea syndrome in the evolution of Acute Coronary syndrome;
†Inclusion

and Exclusion Criteria that are specified for PAP adherence in methodology and/or result publication and/or
supplemental/appendix materials and/or publicly-availably protocol materials. ‡Reported protocol activities specific to PAP
use/initiation/adherence conducted concurrent with randomization; *PAP terminology used generically to represent all forms of
positive airway pressure treatment. Where trials specified type of PAP, the specified type/mode is reported; **Additional
information provided by corresponding author(s).
Abbreviations – PAP, Positive Airway Pressure; CPAP, continuous positive airway pressure; APAP, auto-adjusting positive airway
pressure; Wk, Week(s); Mo, Month(s); (E), Exclusion; NR, None Reported; w/, with; min, Minute(s); PSG, Polysomnogram; q,
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every; FTFV, Face-to-Face Visit(s); prn, as needed; hr, hour(s); nt, night(s); RS, Research Staff; X, times; FAQs, Frequently Asked
Questions; NA, Not Applicable; CV, cardiovascular; SD, secure digital; f/u, follow-up; AHI, apnea hypopnea index; DVD, digital
versatile disk; @, at; L/min, liters per minute; #, number; ETOH, alcohol.
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